In a recent development, an Idaho-based veterinary supply company, MWI Veterinary Supply Inc., has found itself in hot water over its handling of drug shipments to a Putnam County veterinarian, Dr. Clara Ann Mason. The company has agreed to pay a substantial $100,000 settlement, raising questions about its role in ensuring the proper distribution and control of controlled substances.
The Allegations and Concerns
The U.S. Attorneys' office alleged that MWI failed to flag large orders of oxycodone HCL and hydrocodone/acetaminophen placed by Dr. Mason between 2018 and 2023. These orders were deemed excessive for any medical or veterinary practice, prompting concerns about the potential misuse or diversion of these highly addictive medications.
A Troubling Pattern
What makes this case particularly fascinating is the pattern of behavior it reveals. MWI's Suspicious Order Monitoring System flagged Dr. Mason's purchases as suspicious in September 2022, but the company dismissed the alert the very next day. Despite this red flag, MWI continued to fulfill Dr. Mason's orders, including a substantial purchase of 1,300 pills, without further inquiry. This raises a deeper question: Were these actions an oversight, or was there a deliberate lack of vigilance?
The Impact and Implications
The settlement agreement highlights the importance of stringent reporting requirements outlined in the Controlled Substances Act. As Jim Scott, Special Agent in Charge of the DEA's Louisville Division, stated, "Today's settlement serves as a costly reminder that compels MWI to take the threat of drug diversion seriously."
Dr. Mason's Role and Consequences
Dr. Mason, too, faces significant consequences. U.S. Attorneys secured a default judgment against her for $956,709 last year. Judge Robert Chambers found that Dr. Mason not only purchased large quantities of drugs but also failed to secure them properly and keep accurate records. Allegedly, she even attempted to cover her tracks by fabricating records.
A Broader Perspective
This case sheds light on the critical role that supply companies play in preventing drug diversion and abuse. While the focus is often on healthcare professionals and patients, the supply chain is an essential link in ensuring the responsible distribution of controlled substances. As such, companies like MWI must uphold their obligations to protect communities from the devastating consequences of drug misuse.
Conclusion
The settlement between MWI and federal officials serves as a stark reminder of the importance of vigilance and adherence to controlled substance regulations. It highlights the need for a comprehensive approach to addressing drug diversion, involving not only healthcare professionals but also the companies that supply them. As we navigate the complex landscape of healthcare and substance control, cases like these offer valuable lessons and insights into the ongoing battle against drug abuse and its far-reaching impacts.
